Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Keryx Biopharmaceuticals, which is engaged in the acquisition, development and commercialization of pharmaceutical products for the treatment of diseases, including renal disease and cancer, has appointed Michael Tarnok as its interim chairman and CEO, replacing Michael Weiss.
Subscribe to our email newsletter
Mr Tarnok has served on Keryx’s board of directors since September 2007. He spent the majority of his career at Pfizer, which he joined in 1989 as finance director for US manufacturing. From 2000 to 2007, Mr Tarnok served as senior vice president of finance in Pfizer’s US pharmaceuticals division.
Prior to joining Pfizer, Mr Tarnok worked primarily in financial disciplines for ITT Rayonier, Celanese Corporation and Olivetti Corporation of America.